Study on immune function of dendritic cells in patients with esophageal carcinoma

Table 1 Antigen presentation and ability to induce T lympho-cyte proliferation on DCs in peripheral blood from donors and EC patients (%, mean ± SD)

Group	CD80	CD86	CD83	MLR (cpm)
Donor	61.41 ± 7.47	37.28 ± 6.75	5.18 ± 1.59	20000 ± 3000
Patient	41.76 ± 7.35b	29.68 ± 7.32b	4.44 ± 1.17	10000 ± 2000b

^bP < 0.01 vs donor group.

Table 2 Positive staining of CD80, CD86, and S100 proteins in esophageal tissues

Group	Tissue	n	Prevalence	Frequency (%)
CD80	ECT	3 0	8 (26.7%)b	24.37 ± 4.87b
CD80	NET	3 0	18 (60%)	46.25 ± 14.04
CD86	ECT	3 0	12 (40%)	20.37 ± 4.89a
CD86	NET	3 0	13 (43.3%)	26.87 ± 5.89
S-100	ECT	3 0	30 (100%)	56.32 ± 6.25b
S-100	NET	3 0	30 (100%)	72.45 ± 12.34

^aP < 0.05 vs NET group;

^bP < 0.01 vs NET group. ECT: esophageal carcinoma tissue, NET: normal esophageal tissue.

Table 3 Expression of CD83 in esophageal tissues

Group	n	Prevalence (%)	Frequency (%)
ECT	3 0	10(33.3)a	7.82 ± 6.69a
PCT	3 0	18(60)	23.34 ± 19.7

^aP < 0.05 vs PCT group. ECT: esophageal carcinoma tissue, PCT: pericancerous tissue.